CliffBio
biologic

Enhertu

fam-trastuzumab deruxtecan-nxki

Loss of exclusivityDecember 2031projected — 12-year biologic exclusivity estimate
CompanyDaiichi Sankyo →View the full company profile on CliffBio

Drug detail

Brand nameEnhertu
Active ingredientfam-trastuzumab deruxtecan-nxki
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2019
Marketing statusRx

More from Daiichi Sankyo

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Enhertu patent cliff — loss of exclusivity December 2031 | CliffBio